D2B3
Over 98% of all drugs struggle to cross the Blood-Brain Barrier (BBB), hindering their usability against CNS diseases. D2B3’s breakthrough is a patented human monoclonal antibody (Mab), that transiently and highly specifically opens the BBB, achieving high drug penetration to the brain. The lead asset D2B3-01 has shown exceptional performance in in vivo proof of…
-
Manuel Mohr, PhD
Co-founder, Founding CEO
-
Anne Eichmann, PhD
Co-founder, Chief Scientific Advisor
-
Kevin Boyé, PhD
Co-founder, Lead Scientist/Advisor
HarborSite
HarborSite, a Harvard/Wyss Institute spinoff, is pioneering a safe and efficient gene insertion technology to provide curative treatments for rare genetic and common disorders. By engineering compact, simple yet potent enzymes — recombinases — HarborSite can efficiently and precisely integrate large DNA cargos into genomic safe harbors for robust and durable therapeutic gene expression, with…
-
George Church, PhD
SAB Chair
-
Tina Lebar, PhD
SAB Member
Lybra Bio
Lybra Bio is reshaping the treatment landscape of Autoimmune Skin Diseases. They are developing innovative therapeutics platforms aiming to restore the skin’s immune equilibrium in patients suffering from Autoimmune Skin Diseases. Lybra Bio’s first platform combines clinically validated cytokines loaded into an advanced microneedle patch for superior efficacy and patient compliance while bypassing systemic side…
-
Núria Puigmal, PhD
Founder
-
Jamil R. Azzi, PhD, MD
Academic Co-founder
-
Natalie Artzi, PhD
Academic Co-founder
Modulate Bio
Modulate Bio is advancing a new generation of fine-tuned neuro-medicines to treat a range of neurological disorders. Modulate Bio’s platform enables them to precisely treat neurological disorders like Essential Tremor, epilepsy and anxiety by restoring healthy brain receptor function, without overactivating. Modulate Bio has achieved in vivo proof-of-concept in mice and are close to identifying…
-
Dr. Dario Doller, PhD
CSO
-
Kevin Hodgetts, PhD
SAB Chair
RedPoint Oncology
RedPoint Oncology is a targeted precision oncology company, leveraging next-generation antibody-drug conjugates to develop best-in-class therapies for lethal solid tumors with no cure.
-
Mengdie Wang, PhD
Co-founder, CEO
-
Arthur Mercurio, PhD
Co-founder/Advisor
DoriNano
DoriNano aims to harness the potential of DNA origami technology to develop safe, effective, and low-cost combination nanomedicines that have precise cellular targeting with minimal effective doses of cargo for serious diseases. The company’s platform sets out to solve the past limitations of nanoparticles for delivering therapeutic cargo, offering unique advantages such as programmable size…
-
Yang Claire Zeng, MD, PhD
Founder & CEO
Hestia Therapeutics
Hestia Therapeutics, lending its name from the Greek goddess of the hearth, aims to bring inflammatory cells into the tumor microenvironment to unleash anti-tumor effects from within. Currently, more than 70% of cancer patients have tumors that are shielded from the immune cells directed by checkpoint inhibitors to kill cancer cells, leading to disease progression.…
Koi Biotherapeutics
Koi Biotherapeutics is focused on solving a fundamental challenge in CAR T-cell therapy—the lack of long-term persistence of CAR T-cells post-infusion. Koi has developed a novel CAR-Enhancer protein that selectively targets CAR T-cells and promotes their development into memory cells, thereby enhancing their activity and in vivo persistence and eliminating the need for additional engineering…
-
Hamid Mahini, PhD
Co-Founder & CEO
-
Mohammad Rashidian, PhD
Scientific Founder, Assistant Professor at Dana-Farber Cancer Institute/Harvard Medical School
Nucyrna Therapeutics
Nucyrna Therapeutics aims to address the unmet medical needs in ALS and other CNS disorders through its next-gen RNA-targeting technology. Nucyrna’s oligonucleotide platform can target both Nuclear & Cytoplasmic RNA, enabling unique RNA-targeting capacities for addressing complex pathology. Demonstrating a remarkable therapeutic index profile in CNS, the company is focused on neurodegenerative diseases.
-
Damon Wang, PhD
CEO
-
Joseph Klim, PhD
Director of Neuroscience
-
Jonathan Watts, PhD
Scientific Founder & Advisor
-
Robert Brown, MD, DPhil
Scientific Founder & Advisor
-
Evangelos Kiskinis, PhD
Scientific Founder & Advisor
Sphinxion Therapeutics
Sphinxion Therapeutics leverages decades of academic research to bring forward therapeutic options targeting the sphingolipid metabolic pathway as a treatment for rare and common fibrotic diseases. Preliminary animal models in two specific diseases have been effectively treated with AAV gene therapy.
-
Julie Saba, MD, PhD
The John & Edna Beck Chair in Pediatric Cancer Research, UCSF
-
Biren Shah, MBA
Advisor, Revolution Medicines
Cloverleaf Bio
Cloverleaf Bio has developed a new type of RNA therapeutics, based on tRNAs. Its engineered tRNAs have a broad range of applications including oncology, viral infection, and neurodegenerative disorders. Cloverleaf’s patented tRNAs target core components of the cellular translation machinery—tRNA modifying enzymes—that are essential for disease progression.
-
Austin Draycott, PhD
Co-founder & CEO
-
Cole Lewis, M. Phil
Co-founder & CSO
Eascra Biotech
Eascra Biotech is an early-stage nanomedicine start-up launched in Nov 2021. Its proprietary therapeutic delivery platform can deliver RNA, gene editing, and other therapeutic options to hard-to-penetrate tissues such as cartilage, kidney, brain, and some solid tumors. Eascra is partnering with NASA to advance its science here on earth.
-
Mari Anne Snow
Co-founder & CEO
-
Yupeng Chen, PhD
Co-founder & CSO